Ashish Upadhyay

Nephrology Program Director @bu_bmc_renal ; Clinical Professor @BUMedicine; #EBM; #MedEd; Views all mine 🇳🇵🇺🇸🎸👨‍👩‍👧‍👦

[Ashish Upadhyay @asupadh]

Our analysis examining empagliflozin vs dapagliflozin in Stage 3 CKD for kidney outcomes in TriNetX database. Led by @Joyita_4, a formal fellow at @bu_bmc_renal , during her second year of fellowship. @The_BMC @BioMedCentral

https://t.co/jwYtZ4PLJo

[BU/BMC Section of Nephrology @bu_bmc_renal]

Congratulations to our graduating @bu_bmc_renal Nephrology Fellows! We are so proud of your hard work, dedication, and compassion throughout your fellowship. Wishing you all continued success in your next chapter! @connoroneilldee @SanthoshiBavi @SophieClaudel

[Ashish Upadhyay @asupadh]

@NephRodby @CharuThakar @kidney_boy I thought the signals from earlier French trials on avoiding RRT at least made some sense. But, this one is statistically negative for RRT too- possible 3.9% numerical benefit for HCO3 didn’t reach statistical significance.

[Kenar Jhaveri @kdjhaveri]

Another win for IgAN https://t.co/Vafnx8GPmm @TheLancet Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

[Ashish Verma, MD @AshuNephro]

Predictors of variability in urine albumin to creatinine ratio in the general U.S. adult population @SophieClaudel @bu_bmc_renal @The_BMC @BUMedicine @AmJNephrol
https://t.co/hE1APM8xA4

[BU/BMC Section of Nephrology @bu_bmc_renal]

Congratulations to our second year fellow Dr. Jaeine Lee for receiving the @BUmedical McCahan Day “Best resident/fellow abstract award” for her project with @DeepthiGunasek1 “Integrating POCUS curriculum into a Fourth year Internal Medicine Internship Preparation Course”. 🎉👏🎈

[Andrea Angioi, MD, FASN @andreaangioi]

Most kidney trials whisper.
This one doesn’t.

@NEJM Phase 3 interim analysis in NEJM:
telitacicept cut proteinuria by 58.9% vs 8.8% placebo in high-risk IgA nephropathy.

eGFR at 39 weeks: -1.0% vs -7.7%.

Dual BAFF/APRIL blockade may be hitting disease upstream.
#IgAN #Nephrology #KidneyDisease #Glomerulonephritis

[Brendon Neuen @brendonneuen]

Now online: The largest global validation of AHA PREVENT & ESC SCORE2 cardiovascular risk tools. Across ~6.5M people, both performed comparably across geographies & albuminuria further improved risk prediction

Open access in @NatureMedicine:
https://t.co/HiSjXc01rI

[NEJM @NEJM]

Presented at #ISNWCN:

Alternative complement pathway overactivation contributes to IgA nephropathy. In a placebo-controlled trial, iptacopan, a complement factor B inhibitor, significantly slowed kidney-function decline in patients with IgA nephropathy. Full phase 3 APPLAUSE-IgAN trial results: https://t.co/RD5a9ILL7X

@ISNWCN

[Graham Abra, MD @GrahamAbra]

Why should IM residents consider a career in Nephrology

Gen Neph clinic today

- Genetic testing for type IV collagen gene variants
- Perc vs lap PD cath placement
- GDMT for DKD
- Preemptive kidney tx
- Parathyroidectomy
- AMKD
- Sibeprelimab for IgAN
- Dialysis modality ed

[Brian Rifkin, MD @brian_rifkin]

Intern: The nephrology consult says to try a higher dose of lasix.
Attending: OK, does it say a specific dose or schedule?
Intern: 1 gram/24 hours
Attending: 🤯🤯🤯 What ⁉️💦💦💦

[Eric Weinhandl @eric_weinhandl]

Press release about RAINIER trial of povetacicept in IgA nephropathy. #NephJC
https://t.co/Ch3P03hLDi

[NEJM @NEJM]

In adults with type 1 diabetes and chronic kidney disease with albuminuria, the decrease in the urinary albumin-to-creatinine ratio was significantly greater with finerenone than with placebo. Full phase 3 FINE-ONE trial results: https://t.co/E2ThxUUtfX

Editorial: Finerenone for Diabetic Kidney Disease in Type 1 Diabetes — A Fine Answer? https://t.co/xUQ07dMJwt

[Ashish Verma, MD @AshuNephro]

Albuminuria is common across cardiovascular–kidney–metabolic (CKM) phenotypes in the U.S. 🇺🇸
Using NHANES 2011–2020 (Diabetes, Obesity and Metabolism), we show:
• 11% with diabetes alone
• 7% with HTN alone
• >50% with advanced CKM phenotypes https://t.co/aek7r2wgde @SophieClaudel @waikarss @bu_bmc_renal

[Daniel Coyne @DrDanMO]

Epoetin: From life-saving to dangerous therapy in dialysis 1989-2005
This is a clinical history of the 5th biologic protein approved by the FDA under the brand name EPOGEN. Use of epoetin had an immediately life-saving impact on management of anemia in CKD patients. 1/

[Santhoshi Bavi, MBBS 🇮🇳🇺🇸 @SanthoshiBavi]

https://t.co/xNHcH8G1VH
Today’s trainees will define the future of medicine. Our survey exposes gaps in trainee awareness of transplant barriers for undocumented immigrants—showing why equity-focused training is essential. Kudos to @KatieRizzolo for conceiving this work.

[Daniel Coyne @DrDanMO]

Important analysis. We greatly overestimate the benefit SGLT2i drugs have for low risk populations.
For CKD progression in non-DM with UACR <200 mg/g, effective was 0.16 less events/100 pt-yr; less deaths 0.3/100 pt-yr; hospitalization ARR 3.1/100 pt-yr (largely HF pts).

[Ashish Verma, MD @AshuNephro]

Diabetic kidney disease, biomarkers, and finerenone @asupadh @bu_bmc_renal https://t.co/3Jk9Rky5Fs

[Roger Rodby @NephRodby]

@sciqst @iamnephrologist @kidney_boy @SanjayKalraDr1 @Jithukurian6 @nephromythri @varunkumarbandi @ISNeducation Excluding AKI, oliguria, etc I personally believe there is a lot of HyperK-phobia that is not warranted medically. If the kidney has a problem excreting K, it can do so better at a higher serum K, an adaptation. https://t.co/Tuc9dVupsL

[NDT @NDTsocial]

Immune checkpoint inhibitor–associated nephritis: treatment standard

https://t.co/rKsGiIOmbV